Request Demo
Recent blog posts
Latest Hotspot
8 min read
NCT07641140 LY-M003 Hepatolenticular Degeneration Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07641140 clinical trial report covering LY-M003, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07640984 JR-446 Mucopolysaccharidosis III Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07640984 clinical trial report covering JR-446, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07642635 Semaglutide (Novo Nordisk) Muscular Dystrophy, Duchenne Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07642635 clinical trial report covering Semaglutide (Novo Nordisk), Phase 1/2, endpoints, sponsor, geography, readout timing and development white space
Latest Hotspot
8 min read
NCT07644832 SR-604 Hemophilia B Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07644832 clinical trial report covering SR-604, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07643805 EZH2i(The Institute of Cancer Research) Diffuse Large B-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07643805 clinical trial report covering EZH2i(The Institute of Cancer Research), Phase 1/2, endpoints, sponsor, geography, readout timing and developmen
Latest Hotspot
8 min read
NCT07644039 Pembrolizumab Neoplasm Metastasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07644039 clinical trial report covering Pembrolizumab, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07644403 IMC-001(Immunofoco) Locally Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07644403 clinical trial report covering IMC-001(Immunofoco), Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07646210 iPSC derived cardiac muscle cell (Help Therapeutics) Heart Failure Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07646210 clinical trial report covering iPSC derived cardiac muscle cell (Help Therapeutics), Phase 1/2, endpoints, sponsor, geography, readout timing a
Latest Hotspot
8 min read
ChiCTR2600126711 Apatinib Mesylate Refractory Osteosarcoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
ChiCTR2600126711 clinical trial report covering Apatinib Mesylate, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07647237 GR-2301 Vitiligo Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07647237 clinical trial report covering GR-2301, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07666750 EDV-01 Dysentery, Bacillary Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07666750 clinical trial report covering EDV-01, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07667387 LNP.UCD.ABE Carbamoyl-Phosphate Synthase I Deficiency Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07667387 clinical trial report covering LNP.UCD.ABE, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.